XML 50 R32.htm IDEA: XBRL DOCUMENT
v3.25.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS | SCHEDULE OF ACCOUNTS RECEIVABLE ALLOWANCE OF CREDIT LOSS
Balance at January 1, 2023 |  | $ | 73,000 |
Change in expected credit losses |  |  | 332,000 |
Write-offs, net of recoveries |  |  | (34,000 | )
Balance at December 31, 2023 |  |  | 371,000 |
Change in expected credit losses |  |  | 120,000 |
Write-offs, net of recoveries |  |  | (75,000 | )
Balance at December 31, 2024 |  | $ | 416,000 |
SCHEDULE OF ESTIMATED FAIR VALUE | The following table presents the estimated fair values and the carrying values: SCHEDULE OF ESTIMATED FAIR VALUE
|  | December 31, |
|  | 2024 |  |  | 2023 |
|  | Carrying Value |  |  | Fair Value |  |  | Carrying Value |  |  | Fair Value |
2026 Notes |  | $ | 74,002,000 |  |  | $ | 75,840,000 |  |  | $ | 73,218,000 |  |  | $ | 70,260,000 |
2027 Notes |  | $ | 38,130,000 |  |  | $ | 42,198,000 |  |  | $ | 37,413,000 |  |  | $ | 40,363,000 |
Oaktree Loan |  | $ | 107,407,000 |  |  | $ | 112,932,000 |  |  | $ | 75,254,000 |  |  | $ | 78,633,000 |
SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE | The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2024 and 2023: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE
|  | For the Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Numerator – net loss |  | $ | (17,481,000 | ) |  | $ | (24,411,000 | )
Denominator – weighted average number of shares outstanding, basic and diluted |  |  | 35,650,714 |  |  |  | 32,616,777 |
Net loss per share, basic and diluted |  | $ | (0.49 | ) |  | $ | (0.75 | )
Melt Pharmaceuticals, Inc. [Member] |
SCHEDULE OF INVESTMENT | The following table summarizes the Company’s investments in Melt as of December 31, 2024 and 2023: SCHEDULE OF INVESTMENT
|  | Cost Basis |  |  | Share of Equity Method Losses |  |  | Net Carrying value |
Common stock |  | $ | 5,810,000 |  |  | $ | (5,810,000 | ) |  | $ | - |
Preferred stock |  |  | 18,397,000 |  |  |  | (18,397,000 | ) |  |  | - |
|  | $ | 24,207,000 |  |  | $ | (24,207,000 | ) |  | $ | - |
Surface Ophthalmics, Inc. [Member] |
SCHEDULE OF INVESTMENT | The following table summarizes the Company’s investment in Surface as of December 31, 2024 and 2023: SCHEDULE OF INVESTMENT
|  | Cost Basis |  |  | Share of Equity Method Losses |  |  | Net Carrying value |
Common stock |  | $ | 5,320,000 |  |  | $ | (5,320,000 | ) |  | $ | - |

X
- Definition Tabular disclosure of allowance for credit loss on accounts receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details
Name: | us-gaap_InvestmentTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=HROW_SurfaceOphthalmicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |